The High Cost of GLP-1s: Why Some Americans Are Turning to Unregulated Versions

Despite recent improvements, millions of Americans still struggle to afford GLP-1 medications, leading many to seek cheaper, unregulated alternatives. In this report for our series "GLP-1s: Reshaping America," Stephanie Sy explores the barriers to access and the risks associated with unregulated versions. The high cost of these drugs has created a black market, with patients turning to online sellers and compounding pharmacies that may not adhere to safety standards. The report examines the factors driving the affordability crisis, including insurance coverage gaps and the high list prices set by manufacturers. It also highlights the potential dangers of unregulated GLP-1s, which may contain impurities or incorrect dosages. Patients who feel they have no other option are taking significant risks to obtain these medications. PBS News offers a balanced look at this complex issue, featuring interviews with patients, healthcare providers, and policymakers. As the demand for GLP-1s continues to rise, finding solutions to ensure safe and affordable access is more critical than ever. Watch PBS News for daily, breaking, and live coverage of the stories that shape our world.